PAH therapy reverses blood vessel remodeling in preclinical model
Cereno Scientific’s investigational therapy CS014 was found to reverse remodeling, meaning alterations in structure and arrangement, of pulmonary arteries in a preclinical model of pulmonary arterial hypertension (PAH). According to the company, the new preclinical data “provide the most compelling evidence to date that CS014 offers a…